Table 1.

Behavioral data

Placebo before scan Placebo after/during scan Oxytocin before scan Oxytocin after/during scan t test (after/during scanning)
Faces task
Accuracy (%) 98.8% (13.3) 99.1% (1.7) p = 0.77
Reaction time (ms) 1094 (205) 1105 (194) p = 0.91
Scene task
Accuracy (%) 99.7% (1.0) 100% (0.0) p = 1.00
Reaction time (ms) 898 (171) 899 (140) p = 0.99
STAXIa
State 10.1 (0.4) 10.2 (0.8) 10.6 (1.8) 10.3 (0.8) p = 0.33
Trait 17.7 (3.8) 18.3 (3.6) p = 0.23
MDBFb
Arousal 31.3 (6.3) 34.1 (6.0) 33.9 (4.8) 34.1 (6.8) p = 0.96
Wakefulness 30.1 (9.2) 24.1 (8.9) 32.5 (6.6) 26.2 (7.4) p = 0.28
Emotional valencec 34.2 (4.8) 35.0 (4.5) 35.5 (3.7) 35.6 (5.4) p = 0.56
SAMd
Arousal 3.7 (0.98) 4.3 (0.70) 3.8 (0.68) 4.1 (0.96) p = 0.42
Dominance 3.5 (0.64) 3.6 (0.63) 3.8 (0.56) 3.6 (0.83) p = 1.00
Emotional valencec 1.9 (0.92) 1.5 (0.64) 1.6 (0.51) 1.7 (0.80) p = 0.04
  • A nominally significant reduction in valence in the SAM was not seen in the MDBF. The mean (SD) is shown. ANOVA of drug-by-time of application interactions did not identify any significant effects. Wakefulness (MDBF) was significantly reduced after the scan.

  • a Data are from Spielberger (1988).

  • b One subject failed to fill out a questionnaire for the MDBF (Steyer et al., 1994).

  • c Higher equals more positive.

  • d Data are from Bradley and Lang (1994).